Human Papillomavirus Vaccine
Human papillomavirus vaccine with AS04 adjuvant triggers persistent immune response
Published in Vaccine Weekly, October 25th, 2006
According to recent research from Belgium, "An effective virus-like particle (VLP) based prophylactic vaccine designed to protect against persistent infection with human papillomavirus (HPV) types 16 and 18 and subsequent lesion development will need to induce a strong humoral and cellular immune response capable of providing long-term protection.
"Our objective was to evaluate the ability of an HPV16/18 L1 VLP vaccine formulated with the AS04 adjuvant system (3-O-desacyl-4'-monophosphoryl lipid A (MPL) and aluminium salt) to induce an immune response...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-10-25)
More Articles from Vaccine Weekly
- Cholera Vaccine
Double mutant cholera toxin adjuvants have enhanced immunity without CNS toxicity - Ebola Virus Vaccine
Adenoviral vaccine vector protects against lethal Ebola virus - Influenza Vaccine
ELISpot assay detects cellular immunity after flu vaccine in kidney transplant recipients - Acute Myelogenous Leukemia
Juvaris wins innovation research grant for acute myelogenous leukemia vaccine development - Adenovirus Vector
Adenoviral vectors encoding bone morphogenetic protein-2 retarded bone formation - Adenovirus Vector
Gene therapy increases survival in glycogen storage disease type Ia - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
